Estradiol Completed Phase 3 Trials for one to five years postmenopausal Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00160316Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
NCT00522873Endometrial Safety Study